

Daniel Francis Heitjan, PhD

Southern Methodist University:

Department of Statistics & Data Science
Southern Methodist University
Room 308, Heroy Hall
Dallas, TX 75275-0332
Voice: 214-768-3062
Email: dheitjan@smu.edu

UT Southwestern:

Peter O'Donnell Jr. School of Public Health
UT Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX 75390-9066
Email: daniel.heitjan@utsouthwestern.edu

Personal

- Born at Detroit, Michigan; US citizen.
- Pronunciation of my last name: 'hīt-jən.

Education

- The University of Chicago: 1977–1981.
 - BSc with general honors, Mathematics, June 1981.
- Massachusetts Institute of Technology: 1981–1982.
 - Graduate study in Applied Mathematics, specializing in Statistics.
- The University of Chicago: 1982–1985.
 - MSc, Statistics, March 1984.
 - PhD, Statistics, December 1985.

Professional Positions

- University of California, Los Angeles: 1985–1988.
 - Department of Biomathematics (School of Medicine):
 - * Adjunct Assistant Professor of Biomathematics.
 - Jonsson Comprehensive Cancer Center:

- * Associate Member, 1988.
- The Pennsylvania State University: 1988–1995.
 - Center for Biostatistics & Epidemiology (College of Medicine):
 - * Assistant Professor of Biostatistics, 1988–1992.
 - * Associate Professor of Biostatistics (tenured), 1992–1995.
 - Merck & Company, Inc., Blue Bell, PA:
 - * Stanley S. Schor Visiting Scholar, Clinical Biostatistics & Research Data Systems, 1994–1995.
- Columbia University: 1995–2002.
 - Department of Biostatistics (Mailman School of Public Health):
 - * Visiting Associate Professor of Public Health (Biostatistics), 1995–1996.
 - * Associate Professor of Public Health (Biostatistics), 1996–2001; tenured, 1998.
 - * Professor of Biostatistics, 2001–2002.
 - Herbert Irving Comprehensive Cancer Center:
 - * Member and Director of Biostatistics Resource, 1995–2002.
 - International Center for Health Outcomes Innovation & Research:
 - * Director of Biostatistics, 1996–2002.
- University of Pennsylvania: 2002–2014.
 - Department of Biostatistics & Epidemiology (Perelman School of Medicine):
 - * Professor of Biostatistics (tenured), 2002–2014.
 - * Director, Educational Programs in Biostatistics, 2005–2011.
 - * Chair, Graduate Group in Epidemiology & Biostatistics, 2008–2013.
 - Department of Statistics (Wharton School):
 - * Professor of Statistics, 2003–2014.
 - Abramson Cancer Center:
 - * Member and Director, Biostatistics Unit, 2003–2014.
- Southern Methodist University: 2015–.

- Department of Statistics & Data Science (Dedman College of Humanities & Sciences):
 - * Professor of Statistics & Data Science.
 - * Director, SMU/UTSW Collaborative PhD Program in Biostatistics.
 - * Department Chair, 2019–2025.
- University of Texas Southwestern Medical Center: 2015–.
 - Peter O’Donnell Jr. School of Public Health:
 - * Professor.
 - * Director, SMU/UTSW Collaborative PhD Program in Biostatistics.
 - Simmons Cancer Center.
 - * Member, 2015–.
 - * Member, Educational Advisory Committee, 2023–.

Honors & Awards

- Student awards:
 - National Merit Scholar, University of Chicago, 1977–1981.
 - State of Michigan Legislative Scholar, University of Chicago, 1977–1981.
 - Warner-Lambert Fellow, Statistics Department, University of Chicago, 1984–1985.
 - ENAR Spring Meeting Student Award Paper, 1985.
- Honorary fellowships:
 - Fellow of the American Statistical Association, elected 1997.
 - Fellow of the Institute of Mathematical Statistics, elected 2012.
 - Fellow of the Society for Clinical Trials, elected 2017.
- Invited lectures:
 - Distinguished Speaker, Department of Biostatistics, UT M. D. Anderson Cancer Center, 2015.12.

- Distinguished Lecturer, Department of Statistical Sciences & Operations Research and Department of Biostatistics, Virginia Commonwealth University, 2020.02.
- Robert F. Woolson Lecturer, Department of Biostatistics, University of Iowa, 2023.02.
- Other awards:
 - Stanley S. Schor Visiting Scholar, Merck Research Laboratories, 1994–1995.
 - 1994 CDC & ATSDR Statistics Award, recognizing statistical publication # 12 below.
 - Donald B. Owen Award, San Antonio Chapter of the American Statistical Association, 2017.

Professional Societies

- American Statistical Association: member 1982–, elected Fellow 1997.
- International Biometric Society: member 1984–2021.
- Institute of Mathematical Statistics: member 1987–, elected Fellow 2012.
- Society for Clinical Trials: member 1998–, elected Fellow 2017.

Professional Service Positions

- American Statistical Association:
 - Program Chair, Biometrics Section, 2002 Joint Statistical Meetings.
 - Chair, Program Committee, 2005 Joint Statistical Meetings.
 - Chair-Elect (2008), Chair (2009), Past Chair (2010), Biometrics Section.
 - Member, Scientific Organizing Committee, International Conference on Health Policy Statistics, 2015.
 - Member, Advisory Panel, North Texas Chapter, 2025–.
- International Biometric Society, Eastern North American Region:
 - Elected member, Regional Committee, 2009–2011.

- President-Elect (2012), President (2013), Past President (2014).
- Korean International Statistical Society: Board of Directors, 2012–2016.
- Society for Clinical Trials: Student Scholarship Committee, 2020.

Papers Published or In Press—Statistical

1. **Heitjan DF** (1989). Inference from grouped continuous data: A review (with discussion). *Statistical Science* **4**, 164–183.
2. **Heitjan DF**, Rubin DB (1990). Inference from coarse data *via* multiple imputation with application to age heaping. *Journal of the American Statistical Association* **85**, 304–314.
3. **Heitjan DF** (1991). Generalized Norton-Simon models of tumor growth. *Statistics in Medicine* **10**, 1075–1088.
4. **Heitjan DF** (1991). Nonlinear modeling of serial immunologic data: A case study. *Journal of the American Statistical Association* **86**, 891–898.
5. **Heitjan DF** (1991). Regression with bivariate grouped data. *Biometrics* **47**, 549–562.
6. **Heitjan DF**, Little RJA (1991). Multiple imputation for the Fatal Accident Reporting System. *Applied Statistics* **40**, 13–29.
7. **Heitjan DF**, Rubin DB (1991). Ignorability and coarse data. *Annals of Statistics* **19**, 2244–2253.
8. **Heitjan DF**, Derr JA, Satyaswaroop PG (1992). The multi-site tumor transplantation model for human endometrial carcinoma: A statistical evaluation. *Cell Proliferation* **25**, 193–203.
9. **Heitjan DF**, Houts PS, Harvey HA (1992). A decision-theoretic evaluation of early stopping rules. *Statistics in Medicine* **11**, 673–683.
10. **Heitjan DF** (1993). Ignorability and coarse data: Some biomedical examples. *Biometrics* **49**, 1099–1109.
11. **Heitjan DF**, Manni A, Santen RJ (1993). Statistical analysis of *in vivo* tumor growth experiments. *Cancer Research* **53**, 6042–6050.

12. Smith PJ, **Heitjan DF** (1993). Testing and adjusting for departures from nominal dispersion in generalized linear models. *Applied Statistics* **42**, 31–41.
13. **Heitjan DF** (1994). Estimation with missing data. Letter to the editor. *Biometrics* **50**, 580.
14. **Heitjan DF** (1994). Ignorability in general incomplete-data models. *Biometrika* **81**, 701–708.
15. **Heitjan DF** (1994). The NSABP trials. Letter to the editor. *New England Journal of Medicine* **331**, 809–810.
16. **Heitjan DF**, Landis JR (1994). Assessing secular trends in blood pressure: A multiple-imputation approach. *Journal of the American Statistical Association* **89**, 750–759.
17. **Heitjan DF** (1995). Bayesian analysis of a protocol for sampling preserved tumor specimens. *Journal of the American Statistical Association* **90**, 38–44.
18. **Heitjan DF**, Kunselman S (1995). Time until first significant difference in *in vivo* tumor growth experiments. *In Vivo* **9**, 7–9.
19. **Heitjan DF**, Basu S (1996). Distinguishing “missing at random” and “missing completely at random”. *The American Statistician* **50**, 207–213.
20. **Heitjan DF** (1997). Bayesian interim analysis of phase II cancer clinical trials. *Statistics in Medicine* **16**, 1791–1802.
21. **Heitjan DF** (1997). Ignorability, sufficiency and ancillarity. *Journal of the Royal Statistical Society, Series B* **59**, 375–381.
22. **Heitjan DF**, Sharma D (1997). Modeling repeated-series longitudinal data. *Statistics in Medicine* **16**, 347–355.
23. **Heitjan DF** (1998). Coarse data. Pp. 125–127 in *Encyclopedia of Statistical Sciences Update Volume 2*. New York: John Wiley.
24. **Heitjan DF** (1998). Grouped data. In *Encyclopedia of Biostatistics*. New York: John Wiley.
25. **Heitjan DF** (1998). Sheppard’s corrections. In *Encyclopedia of Biostatistics*. New York: John Wiley.

26. **Heitjan DF**, Ten Have TR (1998). Missing data, types of. Pp. 408–411 in *Encyclopedia of Statistical Sciences Update Volume 2*. New York: John Wiley. Will also appear in *Methods and Applications of Statistics in the Life and Health Sciences*, edited by N. Balakrishnan.
27. **Heitjan DF** (1999). Causal inference in a clinical trial: A comparative example. *Controlled Clinical Trials* **20**, 309–318.
28. **Heitjan DF** (1999). Ignorability. Pp. 347–350 in *Encyclopedia of Statistical Sciences Update Volume 3*. New York: John Wiley.
29. **Heitjan DF** (1999). Ignorability and bias in clinical trials. *Statistics in Medicine* **18**, 2421–2434.
30. **Heitjan DF**, Moskowitz AJ, Whang W (1999). Bayesian estimation of cost-effectiveness ratios from clinical trials. *Health Economics* **8**, 191–201.
31. **Heitjan DF**, Moskowitz AJ, Whang W (1999). Problems with interval estimation of the incremental cost-effectiveness ratio. *Medical Decision Making* **19**, 9–15. (Accompanying editorial: Stinnett AA (1999). Is it really so bad to be unambiguously inefficient? The role of dominance in stochastic cost-effectiveness analysis. *Medical Decision Making* **19**, 102–103.)
32. Bagiella E, Sloan RP, **Heitjan DF** (2000). Mixed effects models in psychophysiology. *Psychophysiology* **37**, 13–20.
33. **Heitjan DF** (2000). Fieller’s method and net health benefits. *Health Economics* **9**, 327–335.
34. Bagiella E, **Heitjan DF** (2001). Predicting analysis times in randomized clinical trials. *Statistics in Medicine* **20**, 2055–2063.
35. Hoh J, **Heitjan DF**, Mérette C, Ott J (2001). Ascertainment and anticipation in family studies. *Human Heredity* **51**, 23–26.
36. Chuang J-H, Hripcsak G, **Heitjan DF** (2002). Design and analysis of controlled trials in naturally clustered environments: Implications for medical informatics. *Journal of the American Medical Informatics Association* **9**, 230–238.
37. Hripcsak G, **Heitjan DF** (2002). Measuring agreement in medical informatics reliability studies. *Journal of Biomedical Informatics* **35**, 99–110.

38. **Heitjan DF**, Li H (2004). Bayesian estimation of cost-effectiveness: An importance-sampling approach. *Health Economics* **13**, 191–198.
39. **Heitjan DF**, Kim CY, Li H (2004). Bayesian estimation of cost-effectiveness from censored data. *Statistics in Medicine* **23**, 1297–1309.
40. Ma G, **Heitjan DF** (2004). Sensitivity to nonignorability in frequentist inference. Chapter 16 in *Applied Bayesian Modeling and Causal Inference from Incomplete-Data Perspectives*, edited by Gelman A and Meng X-L. New York: John Wiley.
41. Troxel A, Ma G, **Heitjan DF** (2004). An index of local sensitivity to nonignorability. *Statistica Sinica* **14**, 1221–1237.
42. Xie H, **Heitjan DF** (2004). Sensitivity analysis of causal inference in a clinical trial subject to crossover. *Clinical Trials* **1**, 21–30.
43. Ying G-S, **Heitjan DF**, Chen T-T (2004). Nonparametric prediction of analysis times in randomized clinical trials. *Clinical Trials* **1**, 352–361.
44. Gelman A, Van Mechelen I, Verbeke G, **Heitjan DF**, Meulders M (2005). Multiple imputation for model checking: Completed-data plots with missing and latent data. *Biometrics* **61**, 74–85.
45. Ma G, Troxel AB, **Heitjan DF** (2005). An index of local sensitivity to nonignorable dropout in longitudinal modeling. *Statistics in Medicine* **24**, 2129–2150.
46. Zhang J, **Heitjan DF** (2005). Nonignorable censoring in randomized clinical trials. *Clinical Trials* **2**, 488–496.
47. Donovan JM, Elliott MR, **Heitjan DF** (2006). Predicting event times in clinical trials when treatment arm is masked. *Journal of Biopharmaceutical Statistics* **16**, 343–356.
48. Li H, **Heitjan DF** (2006). A pattern-mixture model for the analysis of censored quality-of-life data. *Statistics in Medicine* **25**, 1533–1546.
49. Ma G, Troxel AB, **Heitjan DF** (2006). Authors’ reply to comment on “An index of local sensitivity to nonignorable dropout in longitudinal modeling”. *Statistics in Medicine* **25**, 3218–3220.

50. Zhang J, **Heitjan DF** (2006). A simple sensitivity analysis tool for nonignorable coarsening: Application to dependent censoring. *Biometrics* **62**, 1260–1268.
51. Donovan JM, Elliott MR, **Heitjan DF** (2007). Predicting event times in clinical trials when randomization is masked and blocked. *Clinical Trials* **4**, 481–490.
52. Mitra N, **Heitjan DF** (2007). Sensitivity of the hazard ratio to nonignorable treatment assignment in an observational study. *Statistics in Medicine* **26**, 1398–1414.
53. Zhang J, **Heitjan DF** (2007). Impact of nonignorable coarsening on Bayesian inference. *Biostatistics* **8**, 722–743.
54. **Heitjan DF**, Asch DA, Rukstalis M, Patterson F, Lerman C (2008). Cost-effectiveness of pharmacogenetic testing to tailor smoking cessation treatment. *The Pharmacogenomics Journal* **8**, 391–399.
55. **Heitjan DF**, Guo M, Ray R, Wileyto EP, Epstein LH, Lerman C (2008). Identification of pharmacogenetic markers in smoking cessation therapy. *The American Journal of Medical Genetics: Neuropsychiatric Genetics* **147B**, 712–719.
56. Wang H, **Heitjan DF** (2008). Modeling heaping in self-reported cigarette counts. *Statistics in Medicine* **27**, 3789–3804.
57. Ying G-S, **Heitjan DF** (2008). Weibull prediction of event times in randomized clinical trials. *Pharmaceutical Statistics* **7**, 107–120.
58. Griffith SD, Shiffman S, **Heitjan DF** (2009). A method comparison study of timeline followback and ecological momentary assessment of daily cigarette consumption. *Nicotine & Tobacco Research* **11**, 1368–1373.
doi:10.1093/ntr/ntp150.
59. Xie H, **Heitjan DF** (2009). Local sensitivity to nonignorability: Dependence on the assumed dropout mechanism. *Statistics in Biopharmaceutical Research* **1**, 243–257.
60. Gastonguay MR, French JL, **Heitjan DF**, Rogers JA, Ahn JE, Ravva P. (2010). Missing data in model-based pharmacometric applications: Points to

- consider. *The Journal of Clinical Pharmacology* **50**, 63S–74S.
doi:10.1177/0091270010378409.
61. Guo M, **Heitjan DF** (2010). Multiplicity-calibrated Bayesian hypothesis tests. *Biostatistics* **11**, 473–483. doi:10.1093/biostatistics/kxq012.
62. Li Y, Wileyto EP, **Heitjan DF** (2010). Modeling smoking cessation data with alternating states and a cure fraction using frailty models. *Statistics in Medicine* **29**, 627–638. doi:10.1002/sim.3825.
63. Li Y, Wileyto EP, **Heitjan DF** (2011). Prediction of individual long-term outcomes in smoking cessation trials. *Biometrics* **67**, 1321–1329; doi:10.1111/j.1541-0420.2011.01578.x.
64. Li Y, Wileyto EP, **Heitjan DF** (2011). Statistical analysis of daily smoking status in smoking cessation clinical trials. *Addiction* **106**, 2039–2046; doi:10.1111/j.1360-0443.2011.03519.x.
65. Li Y, Mick R, **Heitjan DF** (2012). A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials. *Clinical Trials* **9**, 293–302.
66. Liu T, **Heitjan DF** (2012). Sensitivity of the discrete-time Kaplan-Meier estimate to nonignorable censoring: Application in a clinical trial. *Statistics in Medicine* **31**, 2998–3010; doi:10.1002/sim.5454.
67. Wang H, Shiffman S, Griffith S, **Heitjan DF** (2012). Truth and memory: Linking instantaneous and retrospective self-reported cigarette consumption data. *Annals of Applied Statistics* **6**, 1689–1706.
68. Handorf EA, Bekelman JE, **Heitjan DF**, Mitra N (2013). Evaluating costs with unmeasured confounding: A sensitivity analysis for the treatment effect. *Annals of Applied Statistics* **7**, 2062–2080; doi:10.1214/13-AOAS665.
69. Li Y, **Heitjan DF** (2013). A note on the complementary mixture Pareto II distribution. *Communications in Statistics — Theory & Methods* **42**, 201–213; doi:10.1080/03610926.2011.581787.
70. Wileyto EP, Li Y, Chen J, **Heitjan DF** (2013). Assessing the fit of parametric cure models. *Biostatistics* **14**, 340–350; doi:10.1093/biostatistics/kxs043.
71. Ying G-S, **Heitjan DF** (2013). Prediction of event times in the REMATCH Trial. *Clinical Trials* **10**, 197–206; doi:10.1177/1740774512470314.

72. **Heitjan DF**, Ge Z, Ying G-S (2015). Real-time prediction of clinical trial enrollment and event counts: A review. *Contemporary Clinical Trials* **45**, 26–33; doi:10.1016/j.cct.2015.07.010.
73. Li Y, Mick R, **Heitjan DF** (2015). Suspension of accrual in phase II cancer clinical trials. *Clinical Trials* **12**, 128–138, doi:10.1177/1740774514562029.
74. Griffith SD, Shiffman S, Li Y, **Heitjan DF** (2016). Model-based imputation of latent cigarette counts using data from a calibration study. Published online, *International Journal of Methods in Psychiatric Research* **25**, 112–122; doi:10.1002/mpr.1468.
75. Allen C McC, Griffith SD, Shiffman S, **Heitjan DF** (2017). Proximity and gravity: Modeling heaped self-reports. *Statistics in Medicine* **36**, 3200–3215; doi:10.1002/sim.7327.
76. Bender S, **Heitjan DF** (2017). Ignorability conditions for frequentist nonparametric analysis of conditional distributions with incomplete data. *Communications in Statistics — Theory & Methods* **46**, 5252–5264; doi:10.1080/03610926.2015.1099673.
77. **Heitjan DF** (2017). Coarse data. *Wiley StatsRef: Statistics Reference Online*, 1–3. Update based on original article by Daniel Heitjan. John Wiley & Sons, Ltd.
78. **Heitjan DF** (2017). Commentary on Mason *et al.* *Clinical Trials* **14**, 368–369, doi:10.1177/1740774517711443.
79. Ying G-S, Zhang Q, Lan Y, Li Y, **Heitjan DF** (2017). Cure modeling in real-time prediction: How much does it help? *Contemporary Clinical Trials* **59**, 30–37; doi:10.1016/j.cct.2017.05.012.
80. Lan Y, **Heitjan DF** (2018). Adaptive parametric prediction of event times in clinical trials. *Clinical Trials* **15**, 159–168; doi:10.1177/1740774517750633.
81. Ge Z, **Heitjan DF**, Gerber DE, Xuan L, Pruitt SL (2018). Estimating lead-time bias in lung cancer diagnosis of patients with previous cancers. *Statistics in Medicine* **37**, 2516–2529; doi:10.1002/sim.7691.

82. Mokdad AA, Xie X-J, Zhu H, Gerber DE, **Heitjan DF** (2018). Statistical justification of expansion cohorts in phase I cancer trials. *Cancer* **124**, 3339–3345; doi:10.1002/cncr.31577. (With invited discussion by Dahlberg SE, Gray RJ.)
83. Xie H, Gao W, Xing B, **Heitjan DF**, Hedeker D, Yuan C (2018). Measuring the impact of nonignorable missingness using the R package *isni*. *Computer Methods & Programs in Biomedicine* **164**, 207–220; doi:10.1016/j.cmpb.2018.06.014.
84. Handorf EA, **Heitjan DF**, Bekelman JE, Mitra N (2019). Estimating cost-effectiveness from claims and registry data with measured and unmeasured confounders. *Statistical Methods in Medical Research* **28**, 2227–2242; doi:10.1177/0962280218759137.
85. Lan Y, Tang G, **Heitjan DF** (2019). Statistical modeling and prediction of clinical trial recruitment. *Statistics in Medicine* **38**, 945–955.
86. Begg C, Gönen M, **Heitjan DF** (2020). Editorial: Clinical trial design in the era of COVID-19. *Clinical Trials* **17**, 465–466; doi:10.1177/1740774520940230.
87. Li S, Xie X-J, **Heitjan DF** (2020). Flexible, rule-based dose escalation: The cohort-sequence design. *Contemporary Clinical Trials Communications*; doi:10.1016/j.conctc.2020.100541.
88. Chen X, **Heitjan DF**, Greil G, Jeon-Slaughter H (2021). Estimating the optimal timing of surgery from observational data. *Biometrics* **77**, 729–739; doi:10.1111/biom.13311.
89. Chen X, **Heitjan DF**, Greil G, Jeon-Slaughter H (2021). Estimating the optimal timing of surgery by imputing potential outcomes. *Statistics in Medicine* **40**, 6900–6917; doi:10.1002/sim.9217.
90. Li S, **Heitjan DF** (2021). Generalizing clinical trial results to a target population. *Statistics in Biopharmaceutical Research* doi:10.1080/19466315.2021.1942975.
91. Chen H, **Heitjan DF** (2022). Analysis of local sensitivity to nonignorability with missing outcomes and predictors. *Biometrics* **78**, 1342–1352; doi:10.1111/biom.13532.

92. Chen H, **Heitjan DF** (2023). Sensitivity of estimands in clinical trials with imperfect compliance. *International Journal of Biostatistics*; doi:10.1515/ijb-2022-0105.
93. Jing B, Qian Y, **Heitjan DF**, Xie H (2023). Tutorial: Assessing the impact of nonignorable missingness on regression analysis using Index of Local Sensitivity to Nonignorability. *Psychological Methods*; doi:10.1037/met0000616.
94. Yun J, Filardo G, Ahuja V, Bowen ME, **Heitjan DF** (2023). Predicting hospital readmission in Medicaid patients with diabetes using administrative and claims data. *American Journal of Managed Care* **29**; doi:10.37765/ajmc.2023.89409.
95. Yun J, Ahuja V, **Heitjan DF** (2023). Predicting hospital readmission in Medicaid patients with heart failure using administrative and claims data. *Perspectives in Health Information Management* **20**, <https://perspectives.ahima.org>.
96. Chen H, **Heitjan DF** (2024). Response to comments on ‘Sensitivity of estimands in clinical trials with imperfect compliance’. *International Journal of Biostatistics*; doi:10.1515/ijb-2024-0013.
97. **Heitjan DF** (2024). Comment on “Causal interpretation of the hazard ratio in randomized clinical trials” by Fay and Li. *Clinical Trials* **21**, 636–637; doi:10.1177/17407745241243307.
98. **Heitjan DF**, Wang Y, Yun J (2024). Predicting hospital readmission in Medicaid patients with chronic obstructive pulmonary disease. *Respiratory Care* **69**, 541–548; doi:10.4187/respcare.11455.

Papers Published or In Press—Other

99. Ojo-Amaize E, Nishanian P, Keith DE Jr., Houghton RL, **Heitjan D**, Fahey JL, Giorgi JV (1987). Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virus-infected cells. *Journal of Immunology* **139**, 2458–2463.
100. Tobler A, Munker R, **Heitjan D**, Koeffler HP (1987). *In vitro* interaction of recombinant tumor necrosis factor α and all-*trans*-retinoic acid with normal and leukemic hematopoietic cells. *Blood* **70**, 1940–1946.

101. Koeffler HP, **Heitjan D**, Mertelsmann R, Kolitz JE, Schulman P, Itri L, Gunter P, Besa E (1988). Randomized study of 13-*cis*-retinoic acid *v* placebo in the myelodysplastic disorders. *Blood* **71**, 703–708.
102. Martínez-Maza O, Mitsuyasu RT, Miles SA, Giorgi JV, **Heitjan DF**, Sherwin SA, Fahey JL (1989). γ -interferon-induced monocyte major histocompatibility complex class II antigen expression in individuals with acquired immune deficiency syndrome. *Cellular Immunology* **123**, 316–324.
103. Ojo-Amaize E, Nishanian PG, **Heitjan DF**, Rezai A, Esmail I, Korn E, Detels R, Fahey J, Giorgi JV (1989). Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression. *Journal of Clinical Immunology* **9**, 454–461.
104. Gascho JA, Copenhaver GL, **Heitjan DF** (1990). Systolic thickening increases from subepicardium to subendocardium. *Cardiovascular Research* **24**, 777–780.
105. Santen RJ, Manni A, English HF, **Heitjan D** (1990). Androgen-primed chemotherapy — experimental confirmation of efficacy. *Journal of Steroid Biochemistry & Molecular Biology* **37**, 1115–1120.
106. Wengrovitz M, Atnip RG, Gifford RRM, Neumyer MM, **Heitjan DF**, Thiele BL (1990). Wound complications of autogenous subcutaneous infrainguinal arterial bypass surgery: Predisposing factors and management (with discussion). *Journal of Vascular Surgery* **11**, 156–163.
107. English HF, **Heitjan DF**, Lancaster S, Santen RJ (1991). Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer. *Cancer Research* **51**, 1760–1765.
108. Houts PS, Wojtkowiak SL, Simmonds MA, Weinberg GB, **Heitjan DF** (1991). Using a state cancer registry to increase screening behaviors of sisters and daughters of breast cancer patients. *American Journal of Public Health* **81**, 386–388.
109. Williams GD, Palmer C, **Heitjan DF**, Smith MB (1992). Allopurinol preserves cerebral energy metabolism during perinatal hypoxia-ischemia: A ^{31}P NMR study in unanesthetized immature rats. *Neuroscience Letters* **144**, 103–106.

110. Williams GD, Palmer C, Roberts RL, **Heitjan DF**, Smith MB (1992). ^{31}P NMR spectroscopy of cerebral hypoxic-ischemic injury: A model to evaluate neuroprotective drugs in neonates. *NMR in Biomedicine* **5**, 145–153.
111. Yager JY, **Heitjan DF**, Towfighi J, Vannucci RC (1992). Effect of insulin-induced and fasting hypoglycemia on perinatal hypoxic-ischemic brain damage. *Pediatric Research* **31**, 138–142.
112. Mawhinney H, Spector SL, **Heitjan D**, Kinsman RA, Dirks JF, Pines I (1993). As-needed medication use in asthma. Usage patterns and patient characteristics. *Journal of Asthma* **30**, 61–71.
113. Palmer C, Towfighi J, Roberts RL, **Heitjan DF** (1993). Allopurinol administered *after* inducing hypoxia-ischemia reduces brain injury in 7 day old rats. *Pediatric Research* **33**, 405–411.
114. Manni A, Badger B, Wei L, Zaenglein A, Grove R, Khin S, **Heitjan DF**, Shimasaki S, Ling N (1994). Hormonal regulation of IGF-II and IGF binding protein expression by breast cancer cells *in vivo*: Evidence for stromal-epithelial interactions. *Cancer Research* **54**, 2934–2942.
115. Mulsce DJ, Towfighi J, **Heitjan DF**, Vannucci RC (1994). Differences in intra-ischemic temperature influence neurologic outcome after hypothermic circulatory arrest in newborn dogs. *Stroke* **25**, 1433–1442.
116. Sautter RL, Jones S, Weber DI, Lebar WD, **Heitjan DF**, Kopreski MMC, Curcio FD (1994). The prevalence of hepatitis C virus antibody in patients with sexually transmitted diseases (STD) attending a Harrisburg, PA STD clinic. *Infectious Disease in Obstetrics & Gynecology* **1**, 269–274.
117. Towfighi J, Housman C, Vannucci RC, **Heitjan DF** (1994). Effect of unilateral perinatal hypoxic-ischemic brain damage on the gross development of the opposite hemisphere. *Biology of the Neonate* **65**, 108–118.
118. Towfighi J, Housman C, **Heitjan DF**, Vannucci RC, Yager JY (1994). The effect of focal cerebral cooling on perinatal hypoxic-ischemic brain damage. *Acta Neuropathologica* **87**, 598–604.
119. Cataltepe O, Barron TF, **Heitjan DF**, Vannucci RC, Towfighi J (1995). Effect of hypoxia/ischemia on bicuculline-induced seizures in immature rats: Behavioral and electrocortical phenomena. *Epilepsia* **36**, 396–403.

120. Cataltepe O, Vannucci RC, **Heitjan DF**, Towfighi J (1995). Effect of status epilepticus on hypoxic-ischemic brain damage in the immature rat. *Pediatric Research* **38**, 251–257.
121. Manni A, Wechter R, Wei L, **Heitjan D**, Demers L (1995). Phenotypic features of breast cancer cells overexpressing ornithine-decarboxylase. *Journal of Cellular Physiology* **163**, 129–136.
122. Masamura S, Santner SJ, **Heitjan DF**, Santen RJ (1995). Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. *Journal of Clinical Endocrinology & Metabolism* **80**, 2918–2925.
123. Vannucci RC, Towfighi J, **Heitjan DF**, Brucklacher RM (1995). Carbon dioxide protects the perinatal brain from hypoxic-ischemic damage: An experimental study in the immature rat. *Pediatrics* **95**, 868–874.
124. Begemann M, Kashimawo SA, Choi Y-JA, Kim S, Christiansen KM, Duigou G, Mueller M, Schieren I, Ghosh S, Fabbro D, Lampen NM, **Heitjan DF**, Schiff PB, Bruce JN, Weinstein IB (1996). Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. *Clinical Cancer Research* **2**, 1017–1030.
125. Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, **Heitjan DF**, Katz SD (1996). Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: A double-blind, placebo-controlled, randomized crossover trial. *Circulation* **94**, 3184–3189.
126. Ennis RD, Katz AE, de Vries GM, **Heitjan DF**, O'Toole KM, Rubin M, Buttyan R, Benson MC, Schiff PB (1997). Detection of circulating prostate cancer cells via an enhanced reverse transcriptase-polymerase chain reaction in patients with early stage prostate carcinoma: Independence from other pre-treatment characteristics. *Cancer* **79**, 2402–2408.
127. Goluboff ET, **Heitjan DF**, de Vries GM, Katz AE, Olsson CA (1997). Pre-treatment prostate-specific antigen doubling times: Utility in patients before radical prostatectomy (with discussion). *Journal of Urology* **158**, 1876–1879.
128. Papadopoulos KP, Ayello J, Tugulea S, **Heitjan DF**, Williams C, Reiss R, Vahdat LT, Suciu-Foca N, Antman KH, Hesdorffer CS (1997). Harvest quality and factors affecting collection and engraftment of CD34⁺ cells in patients

- with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. *Journal of Hematotherapy* **6**, 61–68.
129. Begemann M, Kashimawo SA, **Heitjan DF**, Schiff PB, Bruce JN, Weinstein IB (1998). Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity. *Anticancer Research* **18**, 2275–2282.
130. Begemann M, Kashimawo SA, Lunn RM, Delohery T, Choi Y-JA, Kim S, **Heitjan DF**, Santella RM, Schiff PB, Bruce JN, Weinstein IB (1998). Growth inhibition induced by Ro 31-8220 and Calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase. *Anticancer Research* **18**, 3139–3152.
131. Ennis RD, Malyszko BK, **Heitjan DF**, Rubin MA, O'Toole KM, Schiff PB (1998). Changes in biochemical disease free survival rates as a result of adoption of the Consensus Conference definition in patients with clinically localized prostate cancer treated with external beam radiotherapy. *International Journal of Radiation Oncology, Biology, Physics* **41**, 511–517.
132. Ennis RD, Malyszko B, Rescigno J, Whitman AE, **Heitjan DF**, O'Toole KM, Rubin M, Schiff PB (1998). Biologic classification as an alternative to anatomic staging for clinically localized prostate cancer: A proposal based on patients treated with external beam radiotherapy. *Urology* **51**, 265–270.
133. Goluboff ET, Saidi JA, Mazer S, Bagiella E, **Heitjan DF**, Benson MC, Olsson CA (1998). Urinary continence after radical prostatectomy: The Columbia experience. *Journal of Urology* **159**, 1276–1280.
134. Rescigno J, **Heitjan DF** (1998). Treatment of head and neck cancer. Letter to the editor. *New England Journal of Medicine* **339**, 1330.
135. Shabsigh A, Chang DT, **Heitjan DF**, Kiss A, Olsson CA, Puchner PJ, Buttyan R (1998). Rapid reduction in blood flow to the rat ventral prostate gland after castration. Preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. *The Prostate* **36**, 201–206.
136. Vahdat LT, Papadopoulos K, Balmaceda C, McGovern T, Dunleavy J, Kaufman E, Fung B, Garrett T, Savage D, Tiersten A, Ayello J, Bagiella E, **Heitjan D**, Antman K, Hesdorffer C. (1998). Phase I trial of sequential high-

- dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. *Clinical Cancer Research* **4**, 1689–1695.
137. Antman KH, **Heitjan DF**, Hortobagyi GN (1999). High-dose chemotherapy for breast cancer. *Journal of the American Medical Association* **282**, 1701–1703.
138. Goluboff ET, Shabsigh A, Saidi JA, Weinstein IB, Mitra N, **Heitjan D**, Piazza GA, Pamukcu R, Buttyan R, Olsson CA (1999). Sulindac sulfone (FGN-1) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. *Urology* **53**, 440–445.
139. Grann VR, Whang W, Jacobson JS, **Heitjan DF**, Antman KH, Neugut AI (1999). Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. *Journal of Clinical Oncology* **17**, 494–500.
140. Hripcsak G, Kuperman GJ, Friedman C, **Heitjan DF** (1999). A reliability study for evaluating information extraction from radiology reports. *Journal of the American Medical Informatics Association* **6**, 143–150.
141. Knell ER, Presant CA, Grann VR, Whang W, Jacobson JS, **Heitjan DF**, Antman KH, Neugut AI (1999). Re-evaluation of the benefits of *BRCA1/2* testing. *Journal of Clinical Oncology* **17**, 1962.
142. Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu S-Z, **Heitjan D**, Ma Y (1999). Activating and dominant inactivating *c-KIT* catalytic domain mutations in distinct clinical forms of human mastocytosis. *Proceedings of the National Academy of Sciences of the USA* **96**, 1609–1614.
143. Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, **Heitjan D**, Fine R, Zuech N, Sawczuk I, Benson M, Olsson CA (1999). Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. *Journal of Clinical Oncology* **17**, 958–967.
144. Rose EA, Moskowitz AJ, Packer M, Sollano JA, Williams DL, Tierney AR, **Heitjan DF**, Meier P, Ascheim DD, Levitan RG, Weinberg AD, Stevenson LW, Shapiro PA, Lazar RM, Watson J, Goldstein D, Gelijns AC for the REMATCH investigators (1999). The REMATCH Trial: Rationale, design and endpoints. *Annals of Thoracic Surgery* **67**, 723–730.

145. Shabsigh A, Tanji N, D'Agati V, Rubin M, Goluboff ET, **Heitjan D**, Kiss A, Buttyan R (1999). Early effects of castration on the vascular system of the rat ventral prostate gland. *Endocrinology* **140**, 1920–1926.
146. Sollano JA, Gelijns AC, Moskowitz AJ, **Heitjan DF**, Cullinane S, Saha T, Chen JM, Roohan PJ, Reemtsma K, Shields EP (1999). Volume-outcome relationships in cardiovascular surgery: New York State, 1990–1995. *Journal of Thoracic & Cardiovascular Surgery* **117**, 419–430.
147. Vitale MG, Krant JJ, Gelijns AC, **Heitjan DF**, Arons RR, Bigliani LU, Flatow EL (1999). Geographic variations in the rates of operative procedures involving the shoulder, including total shoulder replacement, humeral head replacement, and rotator cuff repair. *Journal of Bone & Joint Surgery* **81-A**, 763–772.
148. Whang W, Sisk JE, **Heitjan DF**, Moskowitz AJ (1999). Probabilistic sensitivity analysis in cost-effectiveness: An application from a study of vaccination against pneumococcal bacteremia in the elderly. *International Journal of Technology Assessment in Health Care* **15**, 563–572.
149. Grann VR, Jacobson JS, Whang W, Hershman D, **Heitjan DF**, Antman KH, Neugut AI (2000). Prevention with tamoxifen or other hormones versus prophylactic surgery in *BRCA 1/2* positive women: A decision analysis. *Cancer Journal from Scientific American* **6**, 13–20.
150. Grann VR, Sundararajan V, Jacobson JS, Whang W, **Heitjan DF**, Antman KH, Neugut AI (2000). Decision analysis of tamoxifen for the prevention of invasive breast cancer. *Cancer Journal from Scientific American* **6**, 169–178.
151. Savage DG, Rule SAJ, Tighe M, Garrett TJ, Oster MW, Lee RT, Ruiz J, **Heitjan D**, Keohan ML, Flamm M, Johnson SA (2000). Gemcitabine for relapsed or resistant lymphoma. *Annals of Oncology* **11**, 595–597.
152. Joe AK, Arber N, Bose S, **Heitjan D**, Zhang Y, Weinstein IB, Hibshoosh H (2001). Cyclin D1 overexpression is more prevalent in non-Caucasian breast cancer. *Anticancer Research* **21**, 3535–3539.
153. Mitra N, Schnabel FR, Neugut AI, **Heitjan DF** (2001). Estimating the effect of an intensive screening and surveillance program on stage of breast cancer at diagnosis. *Cancer* **91**, 1709–1715.

154. Rose EA, Gelijns AC, Moskowitz AJ, **Heitjan DF**, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group (2001). Long-term use of a left ventricular assist device for end-stage heart failure. *New England Journal of Medicine* **345**, 1435–1443. (Accompanying editorial: Jessup M (2001). Mechanical cardiac-support devices—dreams and devilish details. *New England Journal of Medicine* **345**, 1490–1493.)
155. Grann VR, Jacobson JS, Thomason D, Hershman D, **Heitjan DF**, Neugut AI (2002). Effects of prevention strategies on survival and quality-adjusted survival of women with *BRCA1/2* mutations: An updated decision analysis. *Journal of Clinical Oncology* **20**, 2520–2529.
156. Hershman D, Sundararajan V, Jacobson JS, **Heitjan DF**, Neugut AI, Grann VR (2002). Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: A cost-effectiveness analysis. *Journal of Clinical Oncology* **20**, 9–16. (Accompanying editorial: Jordan, V. Craig, Morrow, Monica (2002). Chemoprevention of breast cancer: A model for change. *Journal of Clinical Oncology* **20**, 1–3.)
157. Neugut AI, Fleischauer AT, Sundararajan V, Mitra N, **Heitjan DF**, Jacobson JS, Grann VR (2002). Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: A population-based study. *Journal of Clinical Oncology* **20**, 2643–2650.
158. Sundararajan V, Mitra N, Jacobson JS, Grann VR, **Heitjan DF**, Neugut AI (2002). Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. *Annals of Internal Medicine* **136**, 349–357.
159. Savage DG, Cohen NS, Hesdorffer CS, **Heitjan D**, Oster MW, Garrett TJ, Bar M, del Prete S, March R, Lonberg M, Talbot S, Mears JG, Flamm M, Taub RN, Nichols G (2003). Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. *Leukemia & Lymphoma* **44**, 477–481.
160. Smith SJ, Neugut A, **Heitjan DF**, Forde K, Holt P, Santella RM, Luo J-C, Carney W, Ward L, Brandt-Rauf PW (2003). *In situ* quantification of aberrant p53 in colorectal neoplasia. *Biomarkers* **8**, 311–332.

161. Canter RJ, Zhou R, Kesmodel SB, Zhang Y, **Heitjan DF**, Glickson JD, Leeper DB, Fraker DL (2004). Meta-iodobenzylguanidine (MIBG) and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma. *Annals of Surgical Oncology* **11**, 265–273.
162. Gustafson KS, Furth EE, **Heitjan DF**, Fansler ZB, Clark DP (2004). DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens: An approach that utilizes receiver-operating characteristic analysis. *Cancer* **102**, 259–268.
163. Canter RJ, Kesmodel SB, **Heitjan DF**, Veeramachaneni NK, Mokadam NA, Drebin JA, Fraker DL (2005). Suppression of beta-catenin by antisense oligomers augments tumor response to isolated limb perfusion in a rodent model of adenomatous polyposis coli-mutant colon cancer. *Annals of Surgical Oncology* **12**, 733–742.
164. Zhang J, Martins CR, Fansler ZB, Roemer KL, Kincaid EA, Gustafson KS, **Heitjan DF**, Clark DP (2005). DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. *Clinical Cancer Research* **11**, 6544–6549.
165. Anderson K, Jacobson JS, **Heitjan DF**, Zivin JG, Hershman D, Neugut AI, Grann VR (2006). Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. *Annals of Internal Medicine* **144**, 397–406.
166. Mato AR, Riccio BE, Qin L, **Heitjan DF**, Carroll M, Loren A, Porter DL, Perl A, Stadtmauer E, Tsai D, Luger SM (2006). A predictive model for the detection of tumor lysis syndrome during AML induction therapy. *Leukemia & Lymphoma* **47**, 877–883.
167. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, Corbley MJ, Parr M, Ho M, Pastan I, Machuzak M, Benedict W, Zhang X-q, Lord EM, Kanther M, Litzky LA, **Heitjan DF**, June CH, Kaiser LR, Vonderheide RH, Albelda SM (2007). A phase I clinical trial of single-dose intrapleural interferon-beta gene transfer for malignant mesothelioma and metastatic pleural effusions: High rate of anti-tumor immune responses. *Clinical Cancer Research* **13**, 4456–4466.
168. Flaherty KT, Rosen MA, **Heitjan DF**, Gallagher ML, Schwartz B, Schnall MD, O'Dwyer PJ (2008). Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. *Cancer Biology & Therapy* **147B**, 712–719.

169. Haynes K, **Heitjan DF**, Kanetsky PA, Hennessy S (2008). Declining public health burden of digoxin toxicity from 1991 to 2004. *Clinical Pharmacology & Therapeutics* **84**, 90–94.
170. Schnoll RA, Wileyto EP, Pinto A, Leone F, Gariti P, Siegel S, Perkins KA, Dackis C, **Heitjan DF**, Berrettini W, Lerman C (2008). A placebo-controlled trial of modafinil for nicotine dependence. *Drug & Alcohol Dependence* **98**, 86–93.
171. Vira MA, Guzzo T, **Heitjan DF**, Tomaszewski JE, D’Amico A, Wein AJ, Malkowicz SB (2008). Is the biopsy Gleason score important in predicting outcomes for patients after radical prostatectomy once the pathological Gleason score is known? *British Journal of Urology International* **101**, 1232–1236.
172. Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, **Heitjan DF**, June C, Kaiser LR, Ling LE, Albelda SM (2008). Transforming growth factor- β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. *Clinical Cancer Research* **20**, 3966–3974.
173. Carpenito C, Milone M, Hassan R, Simonet J, Lakhil M, Suhoski M, Varela-Rohena A, Haines K, **Heitjan DF**, Albelda S, Carroll R, Riley J, Pastan I, June C (2009). Control of large established tumor xenografts with genetically re-targeted human T cells containing CD28 and CD137 domains. *Proceedings of the National Academy of Sciences of the USA* **206**, 3360–3365.
174. Kim SY, Guevara JP, Kim KM, Choi HK, **Heitjan DF**, Albert DA (2009). Hyperuricemia and risk of stroke: A systematic review and meta-analysis. *Arthritis Care & Research* **61**, 885–892.
175. Mato AR, Fuchs BD, **Heitjan DF**, Mick R, Halpern SD, Shah PD, Jacobs S, Olson E, Schuster SJ, Ujjani C, Chong EA, Loren AW, Miltiades AN, Luger SM (2009). Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignancies. *Cancer Biology & Therapy* **8**, 1–6.
176. Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang L-CS, **Heitjan D**, Snyder LA, Albelda SM (2010). CCL2 blockade augments cancer immunotherapy. *Cancer Research* **70**, 109–118; doi:10.1158/0008-5472.CAN-09-2326.

177. Kim SY, Guevara JP, Kim KM, Choi HK, **Heitjan DF**, Albert DA (2010). Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. *Arthritis Care & Research* **62**, 170–180.
178. Mato AR, Luger S, **Heitjan DF**, Mikkelsen ME, Olson E, Ujjani C, Miltiades AN, Shah P, Shuster SJ, Carroll M, Chauffe AD, Fuchs BD (2010). Elevation in serum lactate at the time of febrile neutropenia in hemodynamically-stable patients with hematologic malignancies is associated with the development of septic shock within 48 hours. *Cancer Biology & Therapy* **9**, 583–587. (Accompanying editorial: Elstrom R (2010). Serum lactate in febrile neutropenia. What can it tell us? *Cancer Biology & Therapy* **9**, 588–589.)
179. Ray R, Mitra N, Baldwin D, Guo M, Patterson F, **Heitjan DF**, Jepson C, Wileyto EP, Wei J, Payne T, Ma JZ, Li M, Lerman C (2010). Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. *Neuropsychopharmacology* **35**, 1374–1382.
180. Schnoll RA, Patterson F, Wileyto EP, **Heitjan DF**, Shields AE, Asch DA, Lerman C (2010). A re-examination of the recommended duration of transdermal nicotine therapy for tobacco dependence: Evidence from a placebo-controlled clinical trial. *Annals of Internal Medicine* **152**, 144–151.
181. Serman DH, Recio A, Haas AR, Vachani A, Katz S, Gillespie CT, Cheng G, Sun J, Pereira L, Moon E, **Heitjan DF**, Litzky L, June C, Vonderheide R, Carroll R, Albelda SM (2010). A phase I clinical trial of repeated intrapleural adenoviral-mediated interferon beta gene transfer for malignant mesothelioma and metastatic pleural effusions. *Molecular Therapy* **18**, 852–860.
182. Christofidou-Solomidou M, Tyagi S, Tan KS, Hagan S, Pietrofesa R, Dukes F, Arguiri E, **Heitjan DF**, Solomides CC, Cengel KA (2011). Dietary flaxseed administered post-thoracic radiation treatment improves survival and mitigates radiation-induced pneumonopathy in mice. *BMC Cancer* **11**:269; doi:10.1186/1471-2407-11-269.
183. Grann VR, Patel PR, Jacobson JS, Warner E, **Heitjan DF**, Ashby-Thompson M, Hershman D, Neugut AI (2011). Comparative effectiveness of screening and prevention strategies among *BRCA1/2*-affected mutation carriers. *Breast Cancer Research & Treatment* **125**, 837–847 doi:10.1007/s10549-010-1043-4.

184. Reshef R, Luskin MR, Kamoun M, Vardhanabhuti S, Tomaszewski JE, Stadtmauer EA, Porter DL, **Heitjan DF**, Tsai DE (2011). Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. *American Journal of Transplantation* **11**, 817–825; doi:10.1111/j.1600-6143.2011.03454.x.
185. Reshef R, Vardhanabhuti S, Luskin MR, **Heitjan DF**, Porter DL, Stadtmauer EA, Tsai DE (2011). Reduction of immunosuppression as initial therapy for post-transplantation lymphoproliferative disorder. *American Journal of Transplantation* **11**, 336–347; doi:10.1111/j.1600-6143.2010.03387.x.
186. Sterman DH, Haas AR, Moon E, Recio A, Schwed D, Vachani A, Katz S, Gillespie C, Cheng G-J, Sun J, Papasavvas E, Montaner LJ, **Heitjan DF**, Litzky L, Friedberg J, Culligan M, June CH, Carroll RG, Albelda SM (2011). A trial of intrapleural adenoviral-mediated interferon- α 2b gene transfer for malignant pleural mesothelioma. *American Journal of Respiratory & Critical Care Medicine*, (PMC3262033).
187. Vogl DT, Pérez, WS, Stadtmauer EA, **Heitjan DF**, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P (2011). Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. *Biology of Blood & Marrow Transplantation* **11**, 1765–1774, (PMC3175301).
188. Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, **Heitjan DF**, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL (2012). Prevention of visceral graft-versus-host disease by inhibition of lymphocyte chemotaxis in patients undergoing allogeneic stem-cell transplantation. *New England Journal of Medicine* **367**, 135–145.
189. Santen RJ, Yue W, **Heitjan DF** (2012). Modeling of the growth kinetics of occult breast tumors: Role in interpretation of studies of prevention and menopausal hormone therapy. *Cancer Epidemiology, Biomarkers & Prevention* **21**, 10381048; doi:10.1158/1055-9965.EPI-12-0043.
190. St. Helen G, Novalen M, **Heitjan DF**, Dempsey D, Peyton J III, Aziziyeh A, Wing VC, George TP, Tyndale RF, Benowitz NL (2012). Reproducibility of the nicotine metabolite ratio in cigarette smokers. *Cancer Epidemiology, Biomarkers & Prevention* **21**, 1105–1114; doi:10.1158/1055-9965.EPI-12-0236.

191. Tizon R, Frey N, **Heitjan DF**, Tan KS, Goldstein S, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D, Davis J, Vozniak M, Fuchs B, Stadtmayer EA, Porter DL (2012). High dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. *Bone Marrow Transplantation*; doi:10.1038/bmt.2011.260 (PMID22307018).
192. El-kassabany NM, Ahmed M, Malkowicz SB, **Heitjan DF**, Isserman JA, Ochroch EA (2013). Comparison between the analgesic efficacy of *transversus abdominis* plane (TAP) block and placebo in open retropubic radical prostatectomy: A prospective, randomized, double-blinded study. *Journal of Clinical Anesthesia* **25**, 459–465; doi:10.1016/j.jclinane.2013.04.009.
193. Kang HC, Tan KS, Keefe SM, **Heitjan DF**, Siegelman ES, Flaherty KT, O'Dwyer PJ, Rosen MA (2013). MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. *American Journal of Roentgenology* **200**, 120–126; doi:10.2214/AJR.12.8536.
194. Nath K, Nelson DS, Ho A, Lee S-C, Darpolor M, Pickup S, Zhou R, **Heitjan DF**, Leeper DB, Glickson JD (2013). ^{31}P and ^1H MRS of DB-1 melanoma xenografts: Lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. *NMR in Biomedicine* **26**, 98–105; doi:10.1002/nbm.2824.
195. Santen RJ, Song Y, Yue W, Wang J-P, **Heitjan DF** (2013). Effects of menopausal hormonal therapy on occult breast tumors. *Journal of Steroid Biochemistry & Molecular Biology* **137**, 150–156; doi:10.1016/j.jsbmb.2013.05.008.
196. Santen RJ, Yue W, **Heitjan DF** (2013). Occult breast tumor reservoir: Biological properties and clinical significance. *Hormones & Cancer* **4**, 195–207; doi:10.1007/s12672-013-0145-y.
197. Schwed-Lustgarten DE, Thompson J, Yu G, Vachani A, Vaidya B, Rao C, Connelly M, Tan KS, **Heitjan DF**, Albelda SM (2013). Use of circulating tumor cell technology (CellSearch) for the diagnosis of malignant pleural effusions. *Annals of the American Thoracic Society* **10**, 582–589; doi:10.1513/AnnalsATS.201303-068OC.
198. Sohal DP, Metz JM, Sun W, Giantonio BJ, Plastaras JP, Ginsberg G, Kochman ML, Teitelbaum UR, Harlacker K, **Heitjan DF**, Feldman MD, Drebin JA,

- O'Dwyer PJ (2013). Toxicity study of gemcitabine, oxaliplatin and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab and radiotherapy, in patients with locally advanced pancreatic cancer. *Cancer Chemotherapy & Pharmacology* **71**, 1485–1491; doi:10.1007/s00280-013-2147-4.
199. Stevenson JP, Kindler HL, Pappasavvas E, Sun J, Jacobs-Small M, Hull J, Schwed D, Ranganathan A, Newick K, **Heitjan DF**, Langer CJ, McPherson JM, Montaner LJ, Albelda SM (2013). Immunological effects of the TGF β -blocking antibody GC1008 in malignant pleural mesothelioma patients. *OncoImmunology* **2**, e26218; doi:10.4161/onci.26218.
200. McCarthy AM, Kontos D, Synnestvedt M, Tan KS, **Heitjan DF**, Schnall M, Conant EF (2014). Screening outcomes following implementation of digital breast tomosynthesis in a general-population screening program. *JNCI* **106**; doi:10.1093/jnci/dju316.
201. Okusanya OT, Holt DF, **Heitjan DF**, Deshpande CG, Venegas O, Jiang J, Judy RP, Dejesus E, Madajewski B, Oh K, Wang MD, Albelda SM, Nie S, Singhal S (2014). Intraoperative near-infrared imaging can identify pulmonary nodules. *Annals of Thoracic Surgery* **98**, 1223–1230; doi:10.1016/j.athoracsur.2014.05.026.
202. Padmanabhan RK, Somasundar VH, Griffith SD, Zhu J, Samoyedny D, Tan KS, Hu J, Liao X, Carin L, Yoon SS, Flaherty KT, DiPaola RS, **Heitjan DF**, Lal P, Feldman MD, Roysam B, Lee WMF (2014). An active learning approach for rapid characterization of endothelial cells in human tumors. *PLoS One* **9**, e90495; doi:10.1371/journal.pone.0090495 (PMC3946171).
203. Rangwala R, Chang C, Hu J, Algazy K, Evans T, Fecher L, Schuchter L, Torigian DA, Panossian J, Troxel A, Tan KS, **Heitjan DF**, Demichele A, Vaughn D, Redlinger M, Alavi A, Kaiser J, Pontiggia L, Davis L, O'Dwyer PJ, Amaravadi RK (2014). Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. *Autophagy* **10**, 1391–1402; doi:10.4161/auto.29119.
204. Rangwala R, Leone R, Chang C, Fecher L, Schuchter L, Kramer A, Tan KS, **Heitjan DF**, Rodgers G, Gallagher M, Piao S, Troxel A, Evans T, Demichele A, Nathanson KL, O'Dwyer PJ, Kaiser J, Pontiggia L, Davis L, Amaravadi RK (2014). Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. *Autophagy* **10**, 1369–1379; doi:10.4161/auto.29118.

205. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelsen T, Wang D, Chang C, Hu J, McAfee Q, Fisher J, Troxel A, Piao S, **Heitjan DF**, Tan KS, Pontiggia L, O'Dwyer PJ, Davis L, Amaravadi RK (2014). A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. *Autophagy* **10**, 1359–1368; doi:10.4161/auto.28984.
206. Vogl DT, Stadtmauer EA, Tan KS, **Heitjan DF**, Davis L, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, Paul TM, Nichols CW, Porter DL, Kaplan J, Mallon G, Bradner JE, Amaravadi RK (2014). Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. *Autophagy* **10**, 1380–1390; doi:10.4161/auto.29264.
207. DeMichele A, Clark A, Tan KS, **Heitjan DF**, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek SM, Gogineni K, Rosen M, Fox KR, O'Dwyer P (2015). CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: Phase II activity, safety and predictive biomarker assessment. *Clinical Cancer Research* **21**, 995–1001; doi:10.1158/1078-0432.CCR-14-2258.
208. Hamilton DA, Mahoney MC, Novalen M, Chenoweth MJ, **Heitjan DF**, Lerman C, Tyndale RF, Hawk LW Jr. (2015). Test-retest reliability and stability of the nicotine metabolite ratio among treatment-seeking smokers. Published on-line, *Nicotine & Tobacco Research* **17**, 1505–1509; doi:10.1093/ntr/ntv031.
209. Kennedy GT, Okusanya OT, Keating JJ, **Heitjan DF**, Deshpande C, Litzky LA, Albelda SM, Drebin JA, Nie S, Low PS, Singhal S (2015). The optical biopsy: A novel method for rapid intraoperative diagnosis of primary pulmonary adenocarcinomas. *Annals of Surgery* **262**, 602–609.
210. Lerman C, Schnoll RA, Hawk LW, Cinciripini P, George TP, Wileyto EP, Swan GE, Benowitz NL, **Heitjan DF**, Tyndale RF for the PGRN-PNAT Research Group (2015). Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: A randomized, double-blind, placebo-controlled trial. *Lancet Respiratory Medicine* **3**, 131–138; doi:10.1016/S2213-2600(14)70294-2.
211. Luskin MR, Heil DS, Tan KS, Choi S, Stadtmauer EA, Schuster, SJ, Porter DL, Vonderheide RH, Bagg A, **Heitjan DF**, Tsai DE, Reshef R (2015). The

- impact of EBV status on characteristics and outcomes of post-transplantation lymphoproliferative disorder. *American Journal of Transplantation* **15**, 2665–2673; doi:10.1111/ajt.13324.
212. Nath K, Nelson DS, **Heitjan DF**, Leeper DB, Zhou R, Glickson JD (2015). Lonidamine induces intracellular tumor acidification and ATP depletion in human breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin. *NMR in Biomedicine* **28**, 281–290; doi:10.1002/nbm.3240.
213. Nath K, Nelson DS, **Heitjan DF**, Zhou R, Leeper DB, Glickson JD (2015). Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan. *NMR in Biomedicine* **28**, 395–403; doi:10.1002/nbm.3260.
214. Okusanya OT, DeJesus EM, Jiang JX, Judy RP, Venegas OG, Deshpande CG, **Heitjan DF**, Nie S, Low PS, Singhal S (2015). Intraoperative molecular imaging can identify lung adenocarcinomas during pulmonary resection. *Journal of Thoracic & Cardiovascular Surgery* **150**, 28–35; doi:10.1016/j.jtcv.2015.05.014.
215. Tyndale RF, Zhu AZX, George TP, Cinciripini P, Hawk LW Jr., Schnoll RA, Swan GE, Benowitz NL, **Heitjan DF**, Lerman C for the PGRN-PNAT Research Group (2015). Lack of associations of *CHRNA5-A3-B4* genetic variants with smoking cessation treatment outcomes in Caucasian smokers despite associations with baseline smoking. *PLoS One* **10**; doi:10.1371/journal.pone.0128109.
216. Kaczmar JM, Tan KS, **Heitjan DF**, Lin A, Ahn PH, Newman JG, Rassekh CH, Chalian AA, O'Malley BW Jr., Cohen RB, Weinstein GS (2016). HPV-related oropharyngeal cancer: Risk factors for treatment failure in patients managed with primary transoral robotic surgery (TORS). *Head & Neck* **38**, 59–65; doi:10.1002/hed.23850.
217. Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, **Heitjan D**, Eliasoff S, Nixon A, Turnbull B, Garmey EG, Gunnarsson O, Walicki M, Ciconte J, Jayaraman L, Senderowicz A, Tellez AB, Hennessy M, Piscitelli A, Vaughn D, Smith A, Haas NB (2016). Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: Results of an investigator-initiated phase I-IIa clinical trial. *Annals of Oncology* **27**, 1579–1585; doi:10.1093/annonc/mdw188.

218. Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, Sun J, **Heitjan DF**, Hwang WT, Litzky L, Yearley JH, Tan KS, Papasavvas E, Kennedy P, Montaner LJ, Cengel KA, Simone CB II, Culligan M, Langer CJ, Albelda SM (2016). Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN α combined with chemotherapy. *Clinical Cancer Research* **22**, 3791–3800; doi:10.1158/1078-0432.CCR-15-2133.
219. Mokdad AA, Yopp AC, Polanco PM, Mansour JC, Reznik SI, Choti MA, Minter RR, Wang SC, **Heitjan DF**, Porembka MR (2017). Adjuvant chemotherapy v. postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer: A propensity score-matched analysis. *JAMA Oncology* doi:10.1001/jamaoncol.2017.2805. (Accompanying editorial: Smyth EC, Cunningham D (2017). Adjuvant chemotherapy following neoadjuvant chemotherapy plus surgery for patients with gastroesophageal cancer — Is there room for improvement? *JAMA Oncology* doi:10.1001/jamaoncol.2017.2792.)
220. Nath K, Roman J, Nelson DS, Guo, L, Lee S-C, Muriuki K, Orlovskiy S, Leeper DB, **Heitjan DF**, Blair IA, Putt ME, Glickson JD (2018). Lonidamine selectively acidifies, de-energizes, and sensitizes WM983B human melanoma xenografts to doxorubicin chemotherapy. *Scientific Reports* **8**, 14654; doi:10.1038/s41598-018-33019-4.
221. Santen RJ, Jewell CM, Yue W, **Heitjan DF**, Raff H, Katzen KS, Cidlowski JA (2018). Glucocorticoid receptor mutations and hypersensitivity to endogenous and exogenous glucocorticoids. *Journal of Clinical Endocrinology & Metabolism* **103**, 3630–3639; doi:10.1210/jc.2018-00352.
222. Santen RJ, **Heitjan DF**, Gompel A, Lumsden MA, Pinkerton JAV, Davis SR, Stuenkel CA (2020). Underlying breast cancer risk and menopausal hormonal therapy. *Journal of Clinical Endocrinology & Metabolism* **105**, e2299–e2307; doi:10.1210/clinem/dgaa073.
223. Santen RJ, **Heitjan DF**, Gompel A, Lumsden MA, Pinkerton JAV, Davis SR, Stuenkel CA (2020). Approach to managing a postmenopausal patient. *Journal of Clinical Endocrinology & Metabolism* **105**; doi:10.1210/clinem/dgaa623.
224. Balagopal A, Morgan H, Dohopolski M, Timmerman R, Shan J, **Heitjan DF**, Liu W, Nguyen D, Hannan R, Garant A, Desai N, Jiang S (2021). PSA-Net:

- Deep learning-based physician style-aware segmentation network for postoperative prostate cancer clinical target volumes. *Artificial Intelligence in Medicine* **121**; doi:10.1016/j.artmed.2021.102195
225. Pruitt SL, Gerber DE, Zhu H, **Heitjan DF**, Maddineni B, Xiong D, Singal AG, Tavvakoli A, Halm EA, Murphy CC (2021). Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer. *Cancer Medicine* **10**, 4752–4767; doi:10.1002/cam4.4036.
226. Pruitt SL, Zhu H, **Heitjan DF**, Rahimi A, Maddineni B, Tavvakoli A, Halm EA, Gerber DE, Xiong D, Murphy CC (2021). Survival of women diagnosed with breast cancer and who have survived a previous cancer. *Breast Cancer Research & Treatment*; doi:10.1007/s10549-021-06122-w.
227. Tsai S, Nguyen H, Ebrahimi R, Barbosa MR, Ramanan B, **Heitjan DF**, Hastings JL, Modrall JG, Jeon-Slaughter H (2021). COVID-19-associated mortality and cardiovascular disease outcomes among U.S. women veterans. *Scientific Reports* **11**, 8497; doi:10.1038/s41598-021-88111-z.
228. Pruitt SL, Tavakkoli A, Zhu H, **Heitjan DF**, Gerber DE, Singal AG, Halm EA, Beg MS, Maddineni B, Kansagra AJ, Murphy CC (2023). Survival of cancer survivors with a new pancreatic cancer diagnosis. *Cancer Medicine* **12**, 200–212; doi:10.1002/cam4.4903.
229. Turer CB, Park JJ, Gupta OT, Ramirez C, Basit MA, **Heitjan DF**, Barlow SE (2023). Electronic phenotypes to distinguish clinician attention to high body mass index, hypertension, lipid disorders, fatty liver, and diabetes in pediatric primary care: Diagnostic accuracy of electronic phenotypes compared to masked comprehensive chart review. *Pediatric Obesity*; doi:10.1111/ijpo.13066.
230. Agarwal S, Basit MA, Bowen ME, **Heitjan DF**, Mai C, Marble K, Pak J, Xiang Z, Lingvay I (2025). Factors influencing the selection of an SGLT2i vs a GLP-1RA as cardioprotective agent in patients with type 2 diabetes. *Frontiers in Cardiovascular Medicine* **12**; doi:10.3389/fcvm.2025.1606198.

Reviews, Discussions, Editorials, & Committee Reports

1. **Heitjan DF** (1990). Review of *Interpreting Data* by Alan J. B. Anderson. *Statistics in Medicine* **9**, 858.

2. **Heitjan DF** (1996). Review of *Observational Studies* by Paul R. Rosenbaum. *SIAM Review* **38**, 529.
3. **Heitjan DF** (1997). Annotation: What can be done about missing data? Approaches to imputation. *American Journal of Public Health* **87**, 548–550.
4. **Heitjan DF** (1998). Review of *The EM Algorithm and Extensions* by Geoffrey J. McLachlan and Thriyambakam Krishnan. *Statistics in Medicine* **17**, 1187.
5. **Heitjan DF** (1998). Analysis of longitudinal binary data from multiphase sampling — Discussion on the papers by Forster and Smith and Clayton *et al.* *Journal of the Royal Statistical Society, Series B* **60**, 89–102.
6. **Heitjan DF** (2009). Review of *Missing Data in Longitudinal Studies: Strategies for Bayesian Modeling and Sensitivity Analysis* by Michael J. Daniels and Joseph W. Hogan. *Biometrics* **65**, 328.
7. **Heitjan DF** (2011). Biology, models and the analysis of tumor xenograft experiments. *Clinical Cancer Research* **17**, 949–952; doi:10.1158/1078-0432.CCR-10-3279.
8. **Heitjan DF** (2011). Incomplete data: What you don't know might hurt you. *Cancer Epidemiology, Biomarkers & Prevention* **8**, 1567–1570; doi:10.1158/1055-9965.EPI-11-0505.
9. Committee on the Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule, Board on Population Health & Public Health Practice, Institute of Medicine of the National Academies (2013). *The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies*. Washington, DC: The National Academies Press.
10. **Heitjan DF** (2016). Review of *Handbook of Missing Data Methodology* by Geert Molenberghs, Garrett Fitzmaurice, Michael G. Kenward, Anastasios Tsiatis, and Geert Verbeke (editors). *Journal of the American Statistical Association* **111**, 443; doi:10.1080/01621459.2016.1154360.

Books

1. Ng HK, **Heitjan DF**, editors (2022). *Recent Advances on Sampling Methods and Educational Statistics: In Honor of S. Lynne Stokes*. Springer.

Grants/Contracts Held as Principal Investigator

- American Cancer Society Institutional Research Grant #IN-109-N, ‘Nonlinear Models for Longitudinal Data’, 1989–1990.
- Merck & Co. grant, ‘Stanley S. Schor Visiting Scholarship’, 1994–1995.
- USPHS grant 1 R01 HL65365 ‘Clinical Trials and Outcomes Research’, 2000–2003.
- MEDTAP International Grant ‘A Bayesian Analysis of Cost-Effectiveness in the REMATCH Trial’, 2001–2002.
- USPHS grant 1 R01 HL68074 ‘Measuring Sensitivity to Nonignorability’, 2001–2005.
- Pilot project on USPHS grant ‘Transdisciplinary research on genetics of complex traits’, 2005–2006.
- USPHS grant 1 R01 CA116723 ‘Statistical Methods in Smoking Cessation Research’, 2007–2010.
- Contract with Digital Health CRC, Ltd. and Western Sydney University, ‘Predictive Modelling of Health Trajectories’, 2020–2023.

Major Editorial Service

- Statistical Consultant, *Annals of Internal Medicine*, 1994–2009.
- Associate Editor, Applications & Case Studies, *Journal of the American Statistical Association*, 1995–2002.
- Member, Editorial Board, *Statistics in Medicine*, 1996–2005.
- Statistical Editor, *Journal of the National Cancer Institute*, 2001–2017.
- Associate Editor, *Statistics in Biopharmaceutical Research*, 2006–2015.
- Associate Editor, *Clinical Trials*, 2008–2020.
- Associate Editor, *Annals of Applied Statistics*, 2014–2021.
- Senior Statistical Editor, *Circulation*, 2016–2018.
- Deputy Editor, *Clinical Trials*, 2020–.

Consulting in Industry & Finance

- Merck & Co., Inc.: 1995–2002.
- InPhoCyte, Inc.: 1995–1996.
- Scios Nova, Inc.: 1996.
- TT International: 1996–1997.
- Advanced Viral Research: 1998.
- Knoll Pharmaceutical: 1998.
- SmithKline Beecham: 1999.
- Aventis Pharmaceutical: 2001.
- AIG Insurance: 2002.
- Sanofi-Aventis: 2005.
- Executive Health Exams, Life Enhancement Research Institute: 2006–2014.
- Ravgen, Inc.: 2005–2007.
- Amgen, Inc.: 2008.
- Apotex, Inc.: 2009.
- Braintree Laboratories, Inc./Sebela Pharmaceuticals, Inc.: 2015–.
- Creatics, Inc.: 2018–2020.
- Bluejay Diagnostics, Inc.: 2021–.
- Medcognetics, Inc.: 2021–2023.
- Cambridge Medical Technologies: 2024–.

Data Monitoring & Project Review Boards

- Trials of Amiloride in cystic fibrosis, Glaxo Inc.: 1993–1994.
- Study and Treatment of Post-Lyme Disease (STOP-LD), NIAID: 1997–2001.
- Trials in GVHD, Protein Design Labs: 2002.
- MicroMed Bridge to Transplantation Study, Columbia University: 2004–2006.
- Trials of Apisol for reducing cholesterol, Wyeth Consumer Healthcare: 2004–2005.
- Carotid Atherosclerosis Progression Trial Investigating Vascular ACAT Inhibition Treatment Effects (CAPTIVATE), Sankyo Pharma Development: 2004–2005.
- Intervention to Improve Memory in Patients with MS (AIMS 2), SUNY-Stony Brook and NIH (NCMRR): 2004–2010.
- HeartMate II Pivotal Trial, Thoratec, Inc.: 2005–2009.
- MicroMed Destination Study, Columbia University: 2005.
- Obesity clinical program, Merck & Co., Inc.: 2005–2008.
- A clinical trial of aspirin and simvastatin for the treatment of patients with pulmonary arterial hypertension (ASA-STAT), NHLBI and Columbia University: 2006–2008.
- Cancer clinical program, Centocor: 2006–2009.
- Diabetes and Periodontal Therapy Trial, NIDCR: 2008–2013.
- Advisory Board, “Functional Bowel Disorders in Chinese Medicine”, International Center for Research on Complementary & Alternative Medicine, University of Maryland, Baltimore: 2010.
- External Advisory Board, SPORE in Gastrointestinal Cancer, University of Michigan: 2009–2013.
- External Scientific Advisory Board, Albert Einstein Cancer Center, Albert Einstein College of Medicine of Yeshiva University: 2012.

- External Scientific Advisory Board, Herbert Irving Comprehensive Cancer Center, Columbia University: 2012.
- Clinical Trials Oversight Committee, Pediatric Research Foundation: 2013–2019.
- DSMB statistician for trials of stem cell transplant in pediatric hematology, New York Medical College: 2013–.
- External Scientific Advisory Board, Moores Cancer Center, University of California San Diego: 2013.
- DSMB Statistician, Heartmate III IDE Study, Thoratec/St. Jude/Abbott: 2014–2019.
- DSMB Statistician and Chair, study of margetuximab plus chemotherapy v. trastuzumab in metastatic breast cancer, MacroGenics, Inc.: 2015–2022.
- DSMB Statistician, MAHOGANY — Study of margetuximab plus INCMGA00012 and chemotherapy or MGD013 and chemotherapy in metastatic or locally advanced, treatment-naïve, HER2-positive gastric or gastroesophageal junction cancer, MacroGenics, Inc.: 2019–2023.
- DSMB Statistician, ARIES HM3 — Antiplatelet removal and hemocompatibility events with the HeartMate 3 pump, Abbott: 2019–2023.
- DMC Statistician, INNOVATE — Investigation of a novel, magnetically levitated VAD for the treatment of refractory left ventricular heart failure, Brio-Health Solutions: 2024–.

Expert Testimony

- Deposition and expert testimony on behalf of Biogen Idec, arbitration proceeding: 2008.
- *Braintree Laboratories, Inc. v. Novel Laboratories, Inc.*: Deposition and expert testimony on behalf of Braintree in US District Court of New Jersey Civil Action No. 3:11-cv-01341 (PGS) (LHG): 2014–2015.
- *Elenza, Inc. v. Alcon Laboratories Holding Corporation, Alcon Research, Ltd., and Novartis AG*: Deposition and expert testimony on behalf of Alcon in Superior Court of Delaware N14C-03-185 MMJ CCLD: 2016–2017.

- *Noven Pharmaceuticals, Inc. v. Actavis Laboratories, UT, Inc.*: Deposition and expert testimony on behalf of Noven in US District Court of Delaware Civil Action: 2018–2019.
- Deposition on behalf of plaintiffs, Women’s Talc Project: 2019–.
- *Guardant Health, Inc. v. Natera, Inc.*: Deposition (twice) and testimony at trial on behalf of plaintiff in US District Court for the Northern District of California, Case No. 3:21-cv-04062: 2022–2024.

Legal Consulting

- *Fallick v. Nationwide Mutual Insurance Co. and Nationwide Life Insurance Co.*: Consultation on statistical methods in summarizing charge data, for the defendant: 1997.
- *Kern v. University of Notre Dame* and *Goltz v. University of Notre Dame*: Analysis of data on alleged sex discrimination in employment practices, for the defendant: 1997.
- Consultant to Next Nutrition in a matter regarding advertising claims: 1999.
- Consultant to attorney for the Consumer Healthcare Products Association in a matter regarding drug safety: 2002.
- *Dr. Reddy’s Laboratories v. Eli Lilly & Co.*: Consultation in a patent infringement case, for the plaintiff: 2002.
- Consultant to attorney for McNeil Pharmaceuticals in a matter regarding advertising claims: 2003.
- Consultant to attorney for Discus Dental: 2004.
- Consultant to attorney for Whittier Law School, accreditation proceeding: 2005.
- Expert consultation on behalf of GlaxoSmithKline, product liability litigation: 2010.
- Expert consultation on behalf of Amgen: 2014–2015.
- *Pfizer, Inc. v. Johnson & Johnson and Janssen Biotech, Inc.*: Statistical consultation on behalf of plaintiff: 2020–2022.

- *Actelion Pharmaceuticals Ltd. et al. v. Bristol-Myers Squibb Co. et al.*: Statistical consultation on behalf of defendant, 2022–2025.
- *United States v. Gilead Sciences, Inc. and Gilead Sciences Ireland UC*: Statistical consultation on behalf of defendant, 2022–2025.
- Expert consultation on behalf of Steam Punk LLC, tax litigation: 2023–2024.

National Scientific Committees

- C-Reactive Protein Pilot Study Planning Committee, NHLBI: 2003.
- Health Care Technology & Decision Science study section, AHRQ: 2003–2007.
- Invited participant, NIH Workshop on the Barriers to Producing Well-Tested, User-Friendly Software for Cutting-Edge Statistical Methodology, NIH: 2008.
- Invited participant, AHRQ Workshop on “Centers for Medicare & Medicaid Services (CMS) Changes in Reimbursement for Hospital-Acquired Infections (HAIs): Setting a Research Agenda”. AHRQ and Columbia University: 2009.
- Institute of Medicine Committee on the Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule: 2012.
- Review committee, Division of Intramural Population Health Research, National Institute of Child Health & Human Development: 2016.